Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants.
Junker D, Becker M, Wagner TR, Kaiser PD, Maier S, Grimm TM, Griesbaum J, Marsall P, Gruber J, Traenkle B, Heinzel C, Pinilla YT, Held J, Fendel R, Kreidenweiss A, Nelde A, Maringer Y, Schroeder S, Walz JS, Althaus K, Uzun G, Mikus M, Bakchoul T, Schenke-Layland K, Bunk S, Haeberle H, Göpel S, Bitzer M, Renk H, Remppis J, Engel C, Franz AR, Harries M, Kessel B, Lange B, Strengert M, Krause G, Zeck A, Rothbauer U, Dulovic A, Schneiderhan-Marra N. Junker D, et al. Among authors: schroeder s. Clin Infect Dis. 2023 Feb 8;76(3):e240-e249. doi: 10.1093/cid/ciac498. Clin Infect Dis. 2023. PMID: 35717657 Free PMC article.
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. Bauer J, et al. Among authors: schroeder s. Nat Commun. 2022 Oct 27;13(1):6401. doi: 10.1038/s41467-022-33746-3. Nat Commun. 2022. PMID: 36302754 Free PMC article.
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M, Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, Walz JS. Heitmann JS, et al. Among authors: schroeder sm. Nat Commun. 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0. Nat Commun. 2023. PMID: 37596280 Free PMC article. Clinical Trial.
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissman IL, Rammensee HG, Walz JS. Nelde A, et al. Among authors: schroeder sm. Blood Cancer Discov. 2023 Nov 1;4(6):468-489. doi: 10.1158/2643-3230.BCD-23-0020. Blood Cancer Discov. 2023. PMID: 37847741 Free PMC article.
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification.
Hoenisch Gravel N, Nelde A, Bauer J, Mühlenbruch L, Schroeder SM, Neidert MC, Scheid J, Lemke S, Dubbelaar ML, Wacker M, Dengler A, Klein R, Mauz PS, Löwenheim H, Hauri-Hohl M, Martin R, Hennenlotter J, Stenzl A, Heitmann JS, Salih HR, Rammensee HG, Walz JS. Hoenisch Gravel N, et al. Among authors: schroeder sm. Nat Commun. 2023 Nov 17;14(1):7472. doi: 10.1038/s41467-023-42692-7. Nat Commun. 2023. PMID: 37978195 Free PMC article.
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.
Tandler C, Heitmann JS, Michel TM, Marconato M, Jaeger SU, Tegeler CM, Denk M, Richter M, Oezbek MT, Maringer Y, Schroeder SM, Schneiderhan-Marra N, Wiesmüller KH, Bitzer M, Ruetalo N, Schindler M, Meisner C, Fischer I, Rammensee HG, Salih HR, Walz JS. Tandler C, et al. Among authors: schroeder sm. Int J Infect Dis. 2024 Feb;139:69-77. doi: 10.1016/j.ijid.2023.11.009. Epub 2023 Nov 26. Int J Infect Dis. 2024. PMID: 38016500 Free article.
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
Seitz CM, Mittelstaet J, Atar D, Hau J, Reiter S, Illi C, Kieble V, Engert F, Drees B, Bender G, Krahl AC, Knopf P, Schroeder S, Paulsen N, Rokhvarguer A, Scheuermann S, Rapp E, Mast AS, Rabsteyn A, Schleicher S, Grote S, Schilbach K, Kneilling M, Pichler B, Lock D, Kotter B, Dapa S, Miltenyi S, Kaiser A, Lang P, Handgretinger R, Schlegel P. Seitz CM, et al. Among authors: schroeder s. Oncoimmunology. 2021 Dec 2;10(1):2003532. doi: 10.1080/2162402X.2021.2003532. eCollection 2021. Oncoimmunology. 2021. PMID: 35686214 Free PMC article.
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, Lang P, Atar D, Schilbach K, Handgretinger R, Schlegel P. Seitz CM, et al. Among authors: schroeder s. Oncoimmunology. 2019 Nov 7;9(1):1683345. doi: 10.1080/2162402X.2019.1683345. eCollection 2020. Oncoimmunology. 2019. PMID: 32002293 Free PMC article.
1,287 results